Automated Prior Authorization Speeds Approval of GLP-1 Therapies
Automated prior authorization using integrated medical claims data accelerates medication access for diabetes patients.
A study by Prime Therapeutics found that two-thirds of prior authorizations for GLP-1 therapies were processed automatically by July 2025.
- Using technology to automate prior authorization simplifies the process.
- Automated prior authorization helps members receive necessary medications seamlessly.
The study's findings were presented as a poster at the Academy of Managed Care Pharmacy (AMCP) Nexus, held at the Gaylord National Resort and Convention Center in National Harbor, Maryland.
Prime’s analysis showed that over 60% of members with diabetes who had a prescription for a GLP-1 medication had their prior authorization approved at the pharmacy counter.
This approach helps avoid unnecessary reviews and manual-review administrative costs.
Author summary: Automation speeds up GLP-1 therapy approvals.